Related Experiment Video

Updated: Sep 3, 2025

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
08:30

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

2.0K

Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases

Xiaopeng Hu1, Xisheng Wang1, Xingkui Xue1

  • 1Medical Research Center, People's Hospital of Longhua, Shenzhen 518109, China.

Molecules (Basel, Switzerland)
|July 27, 2022
PubMed

Insights

Dipeptidyl peptidase 4 (DPP4) inhibitors, used for diabetes, are being investigated for immune-mediated diseases. This review summarizes their therapeutic effects and mechanisms in these conditions.

Area of Science:

  • Immunology
  • Endocrinology
  • Pharmacology

Background:

  • Dipeptidyl peptidase 4 (CD26/DPP4) is an enzyme crucial for glucose metabolism by inactivating incretins GLP and GIP.
  • CD26 is widely expressed in immune cells and plays a key role in T cell activation and regulating cytokines.
  • CD26 inhibitors are established diabetes treatments and are under investigation for immune-mediated diseases and cancer immunology.

Purpose of the Study:

  • To review the therapeutic applications of CD26 inhibitors in immune-mediated diseases.
  • To elucidate the underlying mechanisms of CD26 inhibition in immunological contexts.

Main Methods:

  • Literature review of studies on CD26 inhibitors.
  • Analysis of CD26's role in glucose metabolism and immune cell function.
  • Examination of clinical and preclinical data for immune-mediated diseases.

Main Results:

  • CD26 enzymatic activity impacts both glucose homeostasis and immune responses.
  • CD26 inhibitors demonstrate potential in modulating T cell activation and cytokine profiles.
  • Evidence suggests therapeutic benefits of CD26 inhibitors in various immune-mediated conditions.

Conclusions:

  • CD26 is a significant target for therapeutic intervention in immune-mediated diseases.
  • Understanding CD26's multifaceted roles is key to developing novel immunomodulatory therapies.
  • Further research into CD26 inhibitors may unlock new treatment strategies for autoimmune and inflammatory disorders.
Keywords:
CD26/DPP4 inhibitoranti-tumor immune responseautoimmune diabetescoronavirus-related immunological responsediabetic cardiovascular diseasegraft-versus-host disease (GVHD)immune-mediated diseasesinflammatory bowel disease (IBD)multiple sclerosis (MS)

More Related Videos

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.9K
Murine Model of CD40-activation of B cells12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

12.8K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
224
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
259
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
175
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.2K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K